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Background: Hot flushes and night sweats (vasomotor symptoms) are common menopausal symptoms, often
causing distress, sleep deprivation and reduced quality of life. Although hormone replacement therapy is an
effective treatment, there are concerns about serious adverse events. Non-hormonal pharmacological therapies are
less effective and can also cause adverse effects. Complementary therapies, including acupuncture, are commonly
used for menopausal vasomotor symptoms. While the evidence for the effectiveness of acupuncture in treating
vasomotor symptoms is inconclusive, acupuncture has a low risk of adverse effects, and two small studies suggest
it may be more effective than non-insertive sham acupuncture. Our objective is to assess the efficacy of needle
acupuncture in improving hot flush severity and frequency in menopausal women. Our current study design is
informed by methods tested in a pilot study.
Methods/design: This is a stratified, parallel, randomised sham-controlled trial with equal allocation of participants
to two trial groups. We are recruiting 360 menopausal women experiencing a minimum average of seven moderate
hot flushes a day over a seven-day period and who meet diagnostic criteria for the Traditional Chinese Medicine
diagnosis of Kidney Yin deficiency. Exclusion criteria include breast cancer, surgical menopause, and current
hormone replacement therapy use. Eligible women are randomised to receive either true needle acupuncture or
sham acupuncture with non-insertive (blunt) needles for ten treatments over eight weeks. Participants are blinded
to treatment allocation. Interventions are provided by Chinese medicine acupuncturists who have received specific
training on trial procedures. The primary outcome measure is hot flush score, assessed using the validated Hot Flush
Diary. Secondary outcome measures include health-related quality of life, anxiety and depression symptoms,
credibility of the sham treatment, expectancy and beliefs about acupuncture, and adverse events. Participants will
be analysed in the groups in which they were randomised using an intention-to-treat analysis strategy.
Discussion: Results from this trial will significantly add to the current body of evidence on the role of acupuncture
for vasomotor symptoms. If found to be effective and safe, acupuncture will be a valuable additional treatment
option for women who experience menopausal vasomotor symptoms.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12611000393954 11/02/2009.
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Vasomotor symptoms
Three quarters of menopausal women experience vasomotor
symptoms (VMS), or hot flushes and night sweats [1]. VMS
last an average of 5.2 years [2] but persist in 10% of women
for 15 years or longer [3], and can cause significantly lowered
quality of life due to social embarrassment, sleep deprivation,
and physical discomfort [4]. Risk factors for VMS include
Caucasian ethnicity [5], increased body mass index (BMI)
[6,7], being a smoker [3], feeling stressed [8], financial im-
poverishment [5], and history of depression [8].
VMS management
Hormone replacement therapy (HRT) is a highly effective
treatment for hot flushes, reducing incidence by up to
90% [4]. However, HRT also increases the risk of thrombo-
embolic disease [9], stroke [10], breast cancer [11] and
possibly, dementia [12]. Despite growing interest in non-
hormonal pharmacological therapies such as psychotropic
drugs and selective serotonin reuptake inhibitors (SSRIs)
and serotonin-noradrenaline reuptake inhibitors (SNRIs),
these are not as effective as HRT, and often cause trouble-
some adverse events [4,13,14]. Current evidence does not
support the use of most complementary medicines (CM)
for VMS, with popular treatments such as black cohosh
shown to be ineffective [15,16] and only modest benefits
reported with soy [17]. Yet, over half of the women sur-
veyed in a 2006 Sydney study reported using CM for their
menopausal symptoms, with acupuncturists being the sec-
ond most popular therapists visited [18].
Acupuncture
Acupuncture is a form of Chinese medicine that involves
the insertion of fine needles into specific points on the sur-
face of body known as acupuncture points, or acupoints
[19]. Acupuncture has an excellent safety profile when
practised by qualified acupuncturists, with large prospective
studies reporting that 90% of patients do not experience
any adverse events, and that serious events are rare [20,21].
Some progress has been made on understanding the
neural mechanisms of acupuncture. Acupuncture anal-
gesia is modulated by various transmitters, notably en-
dogenous opioids, serotonin and noradrenaline [22,23].
Acupuncture activates the ‘pain matrix’ - areas of the brain
that have been shown to be consistently activated by nox-
ious stimuli [24] - which includes the insula, an area that
may be involved in the hot flush mechanism [25,26].
Acupuncture for VMS
The thermoneutral zone is the tolerable temperature zone
of the immediate environment within which changes in
core body temperature do not cause compensatory sweat-
ing or flushing [13]. Researchers propose that low sero-
tonin levels and subsequent high noradrenaline levelsduring menopause narrow the thermoneutral zone in
women experiencing VMS. Treatments that raise central
serotonin levels, such as SSRIs or acupuncture, may reduce
hot flushes by normalising the thermoneutral zone [4].
Two systematic reviews, published in 2009, found no
evidence that acupuncture is effective for VMS, and rec-
ommended more rigorous research [27,28]. Since then,
four new clinical trials have published their results
[29-32]. Two of these were pragmatic randomised trials
and reported reductions of mean hot flush scores by 48
to 66% in treatment groups, compared with 28 to 29%
in usual care groups (total n = 451) [29,33]. However, a
contentious issue in acupuncture research is the use of
an adequate sham method in order to control for non-
specific effects of acupuncture. One approach is inser-
tive sham acupuncture, which may involve needling of
acupuncture points that are considered to be ‘irrelevant’
in the treatment of the condition in question, needling
non-acupuncture points, or superficial needling without
eliciting a needle sensation. Insertive sham controls are
increasingly considered to be an inferior acupuncture
control method, with many large randomised controlled
trials (RCTs) failing to show a difference between true
and insertive sham acupuncture [34]. Five such trials for
VMS all failed to demonstrate a difference in mean hot
flush scores between groups receiving true and insertive
sham acupuncture [35-39]. Alternatively, non-insertive
sham acupuncture controls for needling while simulat-
ing a needle-prick sensation using a blunt needle which
does not penetrate the skin [40,41]. These sham needles
have been designed to shorten and ‘telescope’ into them-
selves, and have been validated as plausible simulations of
acupuncture in several studies [41-45]. Three small tri-
als reported true acupuncture to be more effective than
non-insertive sham, with greater reductions in VMS fre-
quency [32] and severity [30,46]. Two of these trials
were published after the 2009 systematic reviews were
conducted [30,32].
Collectively, the extant literature suggests that acu-
puncture treatment as practised in a community setting
can relieve the burden of hot flushes and that the inser-
tion of a needle may represent part of the specific effect
of acupuncture on VMS.Pilot study of acupuncture for VMS
In 2009, CE, MP and CX undertook a pilot project to as-
sess feasibility of a trial of needle acupuncture compared
with non-insertive sham needle for VMS. Twenty-seven
women were randomised, and 20 completed the study.
Study outcomes and participant feedback were used to
modify the design of this current RCT protocol. Our
method was feasible and acceptable to participants (results
not published).
Table 1 Standardised Traditional Chinese Medicine (TCM)
history and examination used in the Acupause study
Kidney Yin deficiency scale Kidney Yang
deficiency scale





Feelings of heat in the palms,
soles and chest
Ache and soreness
in the lower back
Dry mouth or dry hard stool Frequency of
micturition
Aching and soreness in the lower
back and knees Dizziness or tinnitus
Low energy and
pale complexion
Examination Red tongue with scant coat Pale tongue
with thin coat
Rapid fine pulse Sunken, fine pulse
without force
Each symptom is scored on a 4-point Likert scale for both frequency and severity
in the previous month. A score of 1 is given for each tongue and pulse
examination that meets the stated criteria.
aThese symptoms receive a double score as they are considered
cardinal symptoms.
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There is a need for safe and effective treatment of meno-
pausal VMS, given the negative impact that hot flushes
can have on quality of life. Acupuncture is a popular treat-
ment amongst midlife women and has a favourable safety
profile. However, evidence for its effectiveness in treating
VMS remains inconclusive, although results from prag-
matic studies and studies using non-insertive sham nee-
dles are promising. We have used findings from our
feasibility study to inform the design of an adequately
powered randomised sham-controlled trial using the non-
insertive sham needle.
Aims and hypotheses
Our primary aim is to assess the efficacy of needle acu-
puncture in improving hot flush severity and frequency in
menopausal women. Our hypothesis is that needle acu-
puncture will result in greater improvement in the severity
and frequency of hot flushes compared to non-insertive




The trial, also known as the ‘Acupause’ trial, is a strati-
fied, single (participant)-blind, parallel, randomised
sham-controlled trial with equal allocation. The clinical
trial results will be reported according to the CON-
SORT guidelines and the Standards for Reporting Inter-
ventions in Clinical Trials of Acupuncture (STRICTA)
guidelines [47,48].
Trial setting
The trial is taking place in 15 private clinics of project acu-
puncturists (Chinese medicine practitioners) in Australia,
located in metropolitan Melbourne, and regional Victoria,
New South Wales, and the Gold Coast, Queensland, be-
tween September 2011 and October 2014.
The trial has been approved by the Human Research Eth-
ics Committees of the University of Melbourne (1135293
16/6/2011); Monash University (2011001242); RMIT Uni-
versity (1135293); and Southern Cross University (ECN-11-
192). It has been registered with the Australian New
Zealand Clinical Trial Registry (ACTRN12611000393954)
and is funded by a Project Grant from the National Health
and Medical Research Council, Australia (APP 1004406).
Participants
A total of 360 women in the late menopausal transition or
postmenopause, who are experiencing hot flushes, are be-
ing recruited. A number of recruitment methods are used
including (i) advertising through social media (Facebook),
University staff and student newsletters, and a health
register in a Melbourne tabloid newspaper; (ii) flyers atgeneral practitioner, menopause outpatient and allied
health surgeries and female-only fitness centres; (iii)
various strategies through Jean Hailes for Women’s
Health (www.jeanhailes.org.au), an Australian national
not-for-profit education and research organisation focus-
ing on women’s health (strategies include utilisation of the
organisation’s research register, media releases, social net-
working connections, website features, and features in
consumer and professional newsletters); and (iv) media ex-
posure (radio, television and print).
Inclusion criteria
We include women if they:
1. Are deemed postmenopausal (at least 12 months
past the final menstrual period) or in the late
menopausal transition (Follicular Stimulating
Hormone/FSH level of 25 IU or greater, amenorrhoea
of ≥ 60 days and currently experiencing VMS) [49].
(Women who have had a hysterectomy are included if
an FSH level is greater than 25 IU and they are
51 years of age or older); and
2. Record a mean hot flush score of at least 14 over
7 days during the run-in period (equivalent to an aver-
age of seven moderately-severe hot flushes a day and
assessed using a validated Hot Flush Diary) [50,51]; and
3. Meet the criteria for the Traditional Chinese
medicine (TCM) diagnosis of Kidney Yin deficiency
determined using a structured Chinese medicine
history and examination [52]. Women are included
if they score higher for Kidney Yin deficiency than
for Kidney Yang deficiency. See Table 1 for details of
the standardised history and examination used.
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made by TCM practitioners in menopausal women who
present with hot flushes [53,54]. We use standardised
TCM diagnosis as an inclusion criterion for several rea-
sons. In clinical practice it is usual for an acupuncturist
to tailor an acupuncture point prescription to fit the
diagnosis that is made after history and examination.
However, individualisation of the acupuncture point
prescription did not impact on treatment outcome in
one pragmatic trial on acupuncture for VMS [54]. By
standardising this TCM diagnostic process, we are cre-
ating a homogenous sample according to TCM diagno-
sis, simplifying the treatment protocol, and ensuring
our findings are applicable to both TCM and western
medical settings.
Exclusion criteria
Women are excluded if they:
1. Are younger than 40 years of age (therefore
diagnosed as having Premature Ovarian Failure) or
have previously been diagnosed with premature
ovarian failure and are less than 50 years of age;
2. Have had a bilateral salpingo-oophorectomy;
3. Have any medical reason to be amenorrheic
(for example pregnancy, hyperprolactinemia,
Cushing’s syndrome);
4. Have poorly controlled hyperthyroidism or
hypothyroidism;
5. Are experiencing VMS that started or became
worse after diagnosis of breast cancer or
commencing treatment for breast cancer;
6. Are currently taking HRT, with the following
washout periods to be observed: transdermal
(four weeks), oral or intrauterine HRT (eight
weeks), progestin implant/oestrogen injectable,
phytoestrogen therapy (three months), oestrogen
pellet/progestin injectable (six months);
7. Have ceased any other treatment for hot flushes
within twelve weeks of screening (including
complementary medicines);
8. Have commenced using any other pharmacological
or complementary therapy for hot flushes in the
past eight weeks;
9. Have commenced using vaginal oestrogen therapy
in the past twelve weeks;
10. Are unable to read or write sufficiently in English to
complete the outcome measures, which require a
Grade 6 reading level;
11. Have had needle acupuncture treatment in the past
two years;
12. Have relative contraindications to acupuncture (use
of anticoagulant drugs, heart valve disease, poorly
controlled diabetes mellitus);13. Are unwilling or unable to attend for acupuncture/
sham acupuncture for ten treatments over eight
weeks; or
14. Are unable to give informed consent.
Changes to eligibility criteria after trial commencement
To facilitate recruitment within the funded study
period, two changes were made to the original eligibility
criteria. Originally, any previous acupuncture experi-
ence was an exclusion criterion. From October 2011,
participants with previous acupuncture experience were
deemed to be eligible, as long as the last needle acu-
puncture treatment was more than two years previously.
Use of the Park Sham Device has been validated in
non-acupuncture naïve participants [43,55], and advice
from the manufacturer was that broadening the inclu-
sion criteria to non-acupuncture naïve participants
was reasonable (personal communication, Dr Jongbae
Park). Setting a two-year period since a participant’s
last acupuncture experience was considered a long
enough time frame to minimise familiarity to acupunc-
ture practice.
In July 2012, in the light of emerging evidence and rec-
ommendations from the Stages of Reproductive Ageing
(STRAW+ 10) Workshop (Harlow, Gass et al. 2012), we
expanded our criteria to include women in the late meno-
pausal transition (a phase now known to be characterised
by oestrogen deficiency and high risk of VMS), assessed
using FSH testing.Trial procedure
See Figure 1 for a flowchart of the trial procedures. Poten-
tial participants complete an initial screening survey,
followed by a TCM questionnaire online or over the tele-
phone with a trained investigator (KN). All details are
stored online in a password-protected survey management
software account. Women who score higher on the Kidney
Yin scale than on the Kidney Yang scale are sent a baseline
Hot Flush Diary (HFD) to complete.
Women recording an average of seven moderately-severe
hot flushes a day over the seven- day period are then
assessed for TCM criteria (tongue and pulse diagnosis) by a
trained acupuncturist (either CE or a project acupunctur-
ist). For quality assurance purposes, the first twenty poten-
tial participants’ tongues assessed are photographed after
obtaining written consent and an expert Chinese medicine
practitioner and researcher (CX) views the de-identified
photographs to reconcile the diagnosis with the clinical pic-
ture. Thereafter, photographs are only taken of participants
if their TCM diagnosis is unclear. Prior to randomisation,
women are requested to provide written informed consent
after discussing trial procedures and risks of acupuncture
with a trained acupuncture researcher (CE/JS).
Figure 1 Flowchart of trial procedures. FSH = Follicular Stimulating Hormone; TCM = Traditional Chinese Medicine; HFD = Hot Flush Diary.
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Providers and standardisation of the intervention
Fifteen project acupuncturists at 15 sites administer the
study interventions. All acupuncturists have obtained a
Bachelor degree in Chinese medicine, have five or more
years of clinical experience and are registered with the
Chinese Medicine Board of the Australian Health Practi-
tioner Regulation Agency.
To optimise fidelity of delivery of the intervention, project
acupuncturists attend a two-hour training session delivered
by the acupuncturist researcher (CE) who developed and
administered the interventions during the pilot trial. Acu-
puncturists receive a detailed training manual and a DVD
demonstrating the use of the Park Sham Device (sham nee-
dle). The training session includes an introduction to basic
clinical research methods and a practical demonstration of
the Park Sham Device, during which acupuncturists gain
‘hands-on’ experience on how to use the sham needle.
Either the acupuncturist researcher (CE) or a trained
non-acupuncturist investigator (SM) in NSW andQueensland, visits project acupuncturists within a few
weeks of their first study participant session to ensure
protocol adherence. During this visit, a treatment is
observed and feedback provided to the acupuncturist. De-
identified photographs of the needling at interstate train-
ing sessions are Emailed to CE so that point location could
be assessed.
Acupuncturists record details of each treatment on in-
dividual Case Report Forms, which are kept in a locked
cupboard in the clinic and returned to the research team
every six months.
Treatment rationale
The standardised treatment protocol is based on TCM
principles and is designed to treat Kidney Yin deficiency.
The protocol was developed by consensus between two
practising acupuncturist researchers (CX and CE) after con-
sidering a textbook, literature review and expert opinions
from three leading international acupuncture researchers
with particular expertise in women’s health.
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acupuncture is yet to be determined [56], this current
study protocol follows the minimum protocols used in
other positive studies of acupuncture for hot flushes. In
particular the positive study by Nir et al. used an average
of six points, and nine treatments were provided [46]. A
literature review suggests that at least ten treatments
should be provided for hot flush treatment [57]. The acu-
puncture points chosen for this trial are included in the
group of eight core acupuncture points that were used in
one pragmatic trial [54] which allowed for individualisa-
tion of the treatment protocol by acupuncturists. How-
ever, no relation was found between choice of particular
acupuncture points and treatment outcome in that study,
suggesting that point specificity may not be of relevance
when using acupuncture to treat hot flushes.
Treatment regimen
All participants receive ten thirty-minute treatments over
eight weeks, twice weekly in the first two weeks and weekly
thereafter. Treatments are provided at no cost to partici-
pants. All attempts are made to minimise missed sessions
and limit breaks between sessions to two weeks or less.
True acupuncture
True acupuncture needles are standard stainless steel,
sterile and disposable, 32-gauge in thickness and 40 mm
in length. Table 2 describes the acupuncture point pre-
scription. A standardised prescription of six acupuncture
points is used unilaterally. Needles are inserted and ma-
nipulated manually until needling sensation (de qi) is ob-
tained, and are retained for 20 [56] minutes with manual
manipulation at 10 minutes. De qi, literally meaning ‘ar-
rival of energy’, is a term used in acupuncture and refers
to a sensation of numbness or distension sometimes




Kidney 6 (KI6/Zhaohai) In the depression below the tip of the
Kidney 7 (KI7/Fuliu) 2 cuna directly above the acupoint Kid
border of the Achilles tendon. (Kidney
between the tip of the medial malleo
Spleen 6 (SP6/Sanyinjiao) 3 cun directly above the tip of the me
Heart 6 (HT6/Yinxi) When the palm faces upward, the po
of the tendon of muscularis flexor car
above the transverse crease of the wr
Conception Vessel 4 (CV4/Guanyuan) On the anterior midline, 3 cun below
Liver 3 (LR3/Taichong) On the dorsum of the foot, in the dep
the junction of the first and second m
aA cun is is a measurement used in locating acupoints, and corresponds to the dist
when the patient’s middle finger is flexed.to acupuncture theory, activation of de qimay be one indi-
cation that acupuncture is exerting its beneficial effects
[56]. Acupuncturists are trained to enquire about specific
needle sensations when providing true acupuncture.
Sham acupuncture
We use a non-insertive sham control, the Park Sham
Needle, which is supported by a base unit consisting of a
plastic ring and guide tube and attached to the skin with
double-sided tape. The needle and base unit is collectively
referred to as the Park Sham Device (see Figure 2). This
sham needle has been validated in both acupuncture-naïve
and acupuncture-experienced participants, and in healthy
volunteers and patients [41,43,44,55,58]. It has been dem-
onstrated to be less likely to induce de qi or the specific
needling sensation than a true acupuncture needle [41].
Participants in the control group receive bilateral
‘needling’ on three non-acupuncture points which are
not located on the same neuromuscular segments as the
prescribed points used in the true acupuncture group,
so as to minimise any segmental effects. Table 3 de-
scribes the sham points used. All other aspects of the
sham intervention (use of the Park Sham Device base
unit, needle retention time and manipulation, asking
about needle sensation, treatment schedule) are as de-
scribed above for the true acupuncture group.
Information provided to participants about acupuncture
Participants are informed, during the process for obtaining
informed consent, that there is a control group, referred
to as a ‘placebo’ group, and that there is a 50% chance of
being randomly allocated to this group or the true acu-
puncture group. All participants are told that the ‘placebo’
needles are designed to stimulate different nerves com-
pared to the true acupuncture needles, and all participants
are aware that ‘placebo’ treatment is not considered activeAcupause study (Unilateral)
Indication Depth of
insertion
medial malleolus Tonifies Kidney Yin up to 3 mm
ney 3 on the anterior
3 is located in the depression
lus and the Achilles tendon)
Tonifies Kidney Yang and
stops night sweating
up to 15 mm
dial malleolus Nourishes Kidney,
Heart and Liver Yin
up to 20 mm
int is on the radial side




up to 3 mm
the umbilicus Strengthens the uterus,
nourishes the kidneys





7 to 12 mm
ance between the two medial ends of the creases of the interphalangeal joints,
Figure 2 Diagram of Park Sham device. Reproduced from Acupuncture in Medicine, Jongbae Park, Adrian White, Clare Stevinson, Edzard Ernst,
Martin James, vol 20, p 168-174, copyright 2002 with permission from BMJ Publishing Group Ltd.
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the acupuncturists remain blinded and receive a pre-
specified pack of needles and instructions as to where to
insert needles for each participant after randomisation.
Withdrawal criteria
Participants can withdraw from the trial at any time. The
data collected up to the time of withdrawal will be in-
cluded in the analysis unless participants specifically re-
quest for their data to be withdrawn, in which case any
unprocessed data will be withdrawn from analysis. This
has been made explicit in the Plain Language Statement
and Consent Form. Should a participant withdraw, a de-
tailed reason (if provided) is recorded in the trial database.
Co-interventions
In order to avoid confounding the results of the trial, partic-
ipants are asked to avoid commencing new pharmaceutical
co-interventions for hot flushes during the intervention
period, such as herbal treatments and HRT. If already on
treatment for hot flushes, participants are requested not to
discontinue this treatment during the trial.Table 3 Points used in the sham acupuncture group in the Ac
Name given to point Location
Abd 1 2 cuna above and 5 cun lateral to the umbil
Arm 1 Midway between the acupoints Lung 5 and
Large intestine 11 on the cubital crease
Thigh 1 On the bulge of the rectus femoris, 5 cun ab
the middle of the superior border of the pa
aA cun is is a measurement used in locating acupoints, and corresponds to the dist
when the patient’s middle finger is flexed.Outcomes
Table 4 summarises the measures and the timing of their
collection during the trial.
Primary outcome measure
The primary outcome measure is the hot flush score at
end-of-treatment (EOT). EOT hot flush score is calculated
from the seven-day HFD which participants commence
immediately upon completing their final treatment. These
diaries have been used in multiple trials of interventions,
and have been shown to be a consistent and reliable
method of evaluating change in VMS [51].
Participants note daily in the diary the number and se-
verity (mild, moderate, severe and very severe) of hot
flushes experienced over a twenty-four hour period for
seven days. The pilot study showed that it was feasible
and acceptable for women to complete the diary over
seven days with minimal missing data. The HFD will be
used to determine three specific measurements: 1) hot
flush frequency; 2) hot flush severity; and 3) a hot flush
score comprising both frequency and severity. These








2 cun lateral and 3 cun proximal
toreal acupoint Spleen 10
L3
ance between the two medial ends of the creases of the interphalangeal joints,
Table 4 Summary of measures collected as part of the Acupause study
Run-in Intervention Follow-up
Measure Data collection instrument Baseline First treatmentb 4 weeks 8 weeks/EOTc 3 months 6 months
Demographic information,














✓ ✓ ✓ ✓ ✓
Credibility and expectancy Credibility Expectancy Questionnaire +
additional question on binding
✓
aPrimary Outcome Measure. VMS, vasomotor symptoms.
bImmediately after the first treatment; cEnd-of-treatment.
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reported/Number of days reported
Hot flush severity = (1 × number of mild hot flushes + 2 ×
number of moderate hot flushes + 3 × number of severe
hot flushes + 4 × number of very severe hot flushes)/
Number of hot flushes reported
Hot flush score = (1 × number of mild hot flushes + 2 ×
number of moderate hot flushes + 3 × number of
severe hot flushes + 4 × number of very severe hot
flushes)/Number of days reported
Secondary outcome measures
i. Hot flush score at other time-points: the primary
outcome measure is the hot flush score at the EOT;
however, hot flush score will also be measured at
four weeks to assess the intermediate effect of acu-
puncture and at three and six months to measure
longer-term outcomes as recommended in the two
recent systematic reviews [27,28].
ii. Health related quality of life: the Menopause-Specific
Quality of Life Questionnaire (MENQOL) is a
validated measure of quality of life and clinical
change during the menopausal transition and is
specific to women in the first eight years post
menopause [59]. It consists of 29 items assessing
four domains: VMS, physical symptoms,
psychological symptoms, and urogenital/sexual
symptoms.
iii. Anxiety and Depression: Hospital Anxiety and
Depression Scale (HADS) is a validated widely-used
14-item self-report scale designed to briefly measure
current anxiety and depressive symptoms in non-
psychiatric hospital patients. It excludes somatic
symptoms, therefore avoiding potential confounding
factors [60]. The HADS comprises two independent
seven-item subscales for anxiety and depression.Anxiety has been demonstrated to be a predictor of
a high placebo response in menopause studies [61].
iv. Expectancy and beliefs about acupuncture: the
Credibility/Expectancy Questionnaire is a validated,
quick and easy-to-administer six-item scale for
measuring treatment expectancy and rationale
credibility for use in clinical outcome studies [62].
This questionnaire is administered once,
immediately after the first treatment.
v. Success of blinding: as surveys to measure the
success of blinding may enhance participants’ focus
on this, we measure this aspect immediately after
the first treatment [63]. There is currently no
validated measure to assess blinding in acupuncture
research. We will use the scale developed by Bang
[64], which ranges from −1 (completely not blinded)
to +1 (perfectly blinded).
Participants’ characteristics and risk factors for hot flushes
Participants complete a Demographics Questionnaire
upon enrolment into the trial, which collects demo-
graphic information and information on risk factors for
hot flushes including:
i. ethnicity [5];
ii. menopausal status - staging system recommended by
the Stages of Reproductive Ageing Workshop [65];
iii. smoking status [3];
iv. alcohol use [7,66];
v. physical activity [66];
vi. previous tubal ligation [67];
vii. history of depression [8];
viii. stress levels using the validated Perceived Stress
Scale 4 [8,68];
ix. average weekly household income [3,68];
x. education level [68];
xi. BMI [6,7]; and
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including types of acupuncture used, date of last
treatment, frequency of use, conditions treated, and
perceived response to acupuncture
Data storage and access
All hard copy information that contains personal infor-
mation on participants or that can be identified is
stored in a secure locked cabinet. Electronic data that
contains personal information or that can be identified
is password-protected on a secure server and can only
be accessed by authorised researchers. Information will
be retained for a minimum of fifteen years after publi-
cation of results.
Sample size calculation
Sample size calculations are based on a two-sample t-
test with 80% power and significance level at 5% for a
two-sided test. We assumed conservatively that the
mean hot flush score at baseline would be 14, the lowest
possible entry score for the trial. Assuming a 50% rela-
tive reduction in the HF scores in the control group due
to the placebo effect, which is the typical response re-
ported in hot flush randomised controlled trials [69], we
anticipate that women in the sham acupuncture group
will have a mean hot flush score of 7 at EOT. To be clin-
ically significant, we expect that women in the true
intervention group to show at least 75% reduction in the
total HF score from baseline, with a mean HF score of 3
at EOT. Based on these assumptions, 266 women (133
per trial group) will be needed to detect hot flush score
difference of 4 (standard deviation (SD) = 11.6 [51]) be-
tween the two trial groups at EOT. This sample size is
sufficient to detect a difference of 0.35 of 1 SD between
the trial groups for the quality of life measures. Sample
size was inflated to 360 women (180 per study group) to
allow for attrition of 26% (experienced in the pilot study)
at the measurement of the primary outcome at the EOT.
Randomisation and allocation concealment
Sequence generation
Participants are randomly allocated to one of two trial
groups: true acupuncture or sham acupuncture, using a
computer-generated randomisation sequence, stratified
by project acupuncturist using block sizes of either eight
or twelve (with block sizes appearing in random order)
within each stratum and an allocation ratio of 1:1. The
research assistant responsible for allocating participants
is not aware of the block sizes used. An independent re-
searcher with no other involvement in the trial used this
allocation sequence to create a password-protected elec-
tronic ‘spreadsheet’ which contains the covert allocation
schedule. The principal investigator (MP) holds the ran-
domisation schedule.Implementation and allocation concealment
Upon confirmation of eligibility of women for the trial
(that is, after completion of the baseline HFD and clin-
ical confirmation of diagnosis of Kidney Yin deficiency),
the unblinded research assistant (KN) uses the spread-
sheet to randomly allocate participants to receive either
real or sham acupuncture. The spreadsheet displays se-
quentially only the next treatment allocation.
The research assistant informs the relevant project acu-
puncturist of the allocation status by mobile phone text
messaging, Email or fax, depending on the acupuncturist’s
preference. Group allocation is indicated only by the list of
acupuncture points for either real or sham acupuncture,
to avoid unblinding should the participant inadvertently
see the communication. As acupoints used for ‘needling’
in real and sham acupuncture groups are different, acu-
puncturists can easily identify group allocation from the
list of points provided. This process can be cross-checked
against the covert randomisation schedule code held by
the principal investigator to ensure no corruption of the
process has occurred. To prevent selection bias, all base-
line information is collected prior to the acupuncturist be-
ing informed of the treatment allocation.
Blinding
The research assistant responsible for randomisation (KN)
and the project acupuncturists who deliver the treatment
to the women are not blind to treatment allocation. Blind-
ing of project acupuncturists is not possible because of the
difference between real and sham acupuncture points used
and the tactile difference between real and sham needling.
Participants and all other investigators are blinded, in-
cluding the study statistician. As outcomes are self-
assessed, outcome assessment is blinded. Data analysis will
be performed where the treatment groups will be identified
as Group A and B. The codes for the treatment groups will
be revealed after the all outcome data collection is com-
pleted at six months.
Safety
Prior to providing consent to participate, participants
are informed of potential adverse events from acupunc-
ture. Common adverse events include fainting, drowsi-
ness, tiredness, temporary increase in symptoms, bruising
and soreness. A practitioner guide to preventing and man-
aging common adverse events is provided in the Practi-
tioner Training Manual. Participants report adverse events
either to the project acupuncturist delivering the interven-
tion or the acupuncturist researcher. The project acupunc-
turist refers to the acupuncturist researcher in the event of
ongoing or unresolved concerns. Serious adverse events
(defined as potentially life-threatening, permanently incap-
acitating or resulting in hospitalisation) are notified to the
study chief investigator (MP) and the Human Research
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project, it is anticipated that telephone advice from a gen-
eral practitioner (MP/CE) and/or acupuncturist researcher
(JS) will be adequate in most cases. If participants require
additional medical advice, they are directed to their gen-
eral practitioner. The expert acupuncturist (CX), who
chairs the Chinese Medicine Board in Australia, is also
available for advice.
Participants who score higher than 15 on the baseline de-
pression and/or anxiety scales will be contacted by a gen-
eral practitioner investigator (CE/MP) to be assessed for
suicide risk and referred to relevant services as required.
Both the relevant project acupuncturist and the partici-
pant complete an Adverse Event Form should the need
arise. The form records the dates and times that the event
began and resolved; a description of the event; the inten-
sity of the event (mild/moderate/severe); an assessment of
the possible relationship to acupuncture, on a four-point
Likert scale ranging from ‘unrelated’ to ‘definitely related’;
the outcome on a five-point Likert scale ranging from
‘completely resolved’ to ‘persistent’; and whether the event
was considered serious (potentially life-threatening, per-
manent incapacitating or resulting in hospitalisation).
Data collection
The Credibility/Expectancy Questionnaire, Case Report
Form, TCM Diagnosis Form and Adverse Events Form are
completed on paper copies. All other outcome measures,
participant characteristics and risk factors for hot flushes
are completed online using a survey management website
(Survey Methods www.surveymethods.com), with paper
copies available for those who prefer to use them. Online
surveys have the advantage of minimising missing data if
completion of survey questions is made mandatory prior
to submitting the survey online. Range checks are also
built into online surveys, and automated reminders are
Emailed. The study acupuncturist and research assistant
(CE and KN) oversee this data management. A reminder
letter/Email is sent after two weeks, followed by a courtesy
telephone call two weeks later by the research assistant
should questionnaires not be returned. Details of treat-
ment dates and follow-up are recorded in a custom-built
password-protected database.
All paper-based data are entered into the same survey
management website by staff blinded to group allocation
at the University of Melbourne. Ten percent of all data
entry will be audited by an independent investigator for
quality assurance purposes.
Statistical methods
Descriptive statistics will be used to summarise baseline
measures and participant characteristics between the two
trial groups and to assess for chance imbalance of import-
ant prognostic factors. Primary outcome is the hot flushscore at EOT. Analysis will account for repeated outcome
measures taken on the same women over 12 months and
stratification by project acupuncturists. Mixed-effects lin-
ear regression model will be used to compare the continu-
ous outcomes between the trial groups and marginal
logistic regression model using generalised estimating
equations with robust standard errors will be used for the
binary outcomes. Where appropriate the baseline measure
of the outcome will be included as a covariate in the regres-
sion model. In addition, factors strongly associated with the
outcome and are found to be imbalanced between the trial
groups at baseline will also be adjusted in the regression
models. Estimates of the intervention effect will be reported
as the difference in means between trial groups for continu-
ous outcomes and odds ratios for binary outcomes, with re-
spective 95% confidence intervals and P-values. Stata 13.0
[70] will be used for the data analyses.
An intention-to-treat analysis strategy will be employed
where all participants will be analysed in the trial group in
to which they were allocated [71]. In the first instance, we
will strive to minimise the extent of missing outcome data
for participants, where all efforts will be made to collect
the primary outcome on participants who withdraw, dis-
continue their treatment or do not respond to the online
survey. However, in the presence of incomplete data, in-
formation collected on the reasons for missing data will be
used to inform the appropriate statistical analysis ap-
proach to handle the missing data. Sensitivity analyses that
capture departures from the assumption of the missing
data mechanism for the primary analysis will also be con-
sidered to assess the robustness of the results.
Secondary analyses
Additional secondary analyses are planned. These will in-
clude (1) exploring the effect acupuncture had on women’s
quality of life, (2) identifying factors that are associated
with a placebo response, (such as anxiety/depression levels
and demographic characteristics such as socioeconomic
status), (3) the association between expectancy and beliefs
and women’s response to acupuncture treatment, and (4)
the credibility of the Park Sham Device.
Data monitoring
As acupuncture has an excellent safety profile, and is
not considered an experimental treatment, no data mon-
itoring committee is required.
Discussion
Hot flushes are a common and potentially disabling symp-
tom during the menopause. While HRT is an effective
treatment, it does not suit all women either because of
concerns over potentially serious adverse events, or be-
cause of relative contra-indications. Many women also
prefer to use natural or complementary therapies where
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hormonal treatments for VMS. However, preliminary
evidence suggests that acupuncture, a popular and safe
treatment for a wide range of conditions, may be effect-
ive for VMS.
We are conducting a randomised sham-controlled trial
on acupuncture for VMS, which builds on the results from
our earlier pilot project during which feasibility of
methods was demonstrated. This robustly designed study
meets methodological benchmarks of adequate random-
isation and allocation concealment procedures, blinding of
outcome assessors and statisticians and utilising intention-
to-treat analysis strategy. The trial method also allows for
Traditional Chinese Medicine diagnosis in the eligibility
criteria and a ‘dose’ of acupuncture reflecting clinical prac-
tice to ensure results are applicable to a broad range of
health practitioners. The trial is appropriately powered to
determine a clinically relevant treatment effect. Our re-
sults will determine the efficacy of acupuncture for treat-
ing VMS in postmenopausal women. In particular, we will
assess the specific effect of insertion of the acupuncture
needle and its contribution to the entire treatment effect.
Our results will inform women suffering with meno-
pausal symptoms and both conventional and Traditional
Chinese Medicine health care professionals on the po-
tential role, if any, of acupuncture in the treatment of
VMS. This will advance the field significantly and, if ef-
fective, will offer an important treatment option to re-
duce VMS and potentially improve quality of life in
women at this important life stage. Future research may
explore the optimal treatment regimen for acupuncture
for VMS.
Trial status
The trial has received funding and recruitment commenced
in late 2011. At the time of submission of this protocol,
project acupuncturists had been trained, participant enrol-
ment was progressing well and data collection was well un-
derway. Trial enrolment closed in March 2014. We
anticipate that all data will be collected by late 2014.
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